Interpreting immunogenicity in oncology clinical trials

By afschroeder • September 1, 2025

Galle PR, Reck M, Pinato DJ, Garcia-Campelo R, Finn RS, Cousin S, Zanghi J, Bernaards CA, Swanson SJ, Morris S, Song Y, Peters S. Interpreting immunogenicity in oncology clinical trials. Cancer Treat Rev. 2025 Aug 25;140:103016. doi: 10.1016/j.ctrv.2025.103016. Epub ahead of print. PMID: 40886486.

Tags: Hematology/Oncology, Publications

Related Posts

American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults

O'Dwyer K, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer J, Hayes-Lattin[...]

Identifying the window of aggressive postpartum breast cancer based on the 21-gene Oncotype DX® test in women with HR+, HER2-negative breast cancer

Zhang S, Queen KJ, Duggirala N, Yang E, Lipsyc-Sharf M, Racz J, Bennett J, Hong K, Suresh Y, Hamilton C, Pitta M, Chien N, La[...]

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

Choueiri TK, Merchan J, Patnaik A, Drakaki A, Rini BI, Rha SY, Lee JL, Ornstein MC, Kumar R, Hwang C, Shao Y, Park SH, Barata[...]